A Very Rare Case of Cutaneous Toxicity of API Protocol

Nadia Filali1*, Samia H Touimi2, G Akimana1, H Elkacemi2, S Elmouhtadi1, H Abahssain1, T Kebdani2, N Benjaafar1, H Errihani1

1Department of Oncology, National Institute of Oncology, Rabat, Morocco
2Department of Radiotherapy, National Institute of Oncology, Rabat, Morocco

Clinical Image

It’s a 36 years old female patient treated 7 years ago for an osteochondroma of the upper third of the left humerus by surgery alone. She was under follow-up since then. 5 months ago, she presented a mass in the same previous location. CT scan showed a locally advanced tumor of the left humerus.

A biopsy of the mass showed a low-grade osteosarcoma with high-grade osteosarcoma differentiation foci.

The remainder of the staging didn’t reveal any metastases.

The patient received 1 course of chemotherapy neoadjuvant to surgery with Adriamycin–Cisplatin–Ifosfamid (API). She presented 3 days later right laterocervical skin lesions which extend in one week to the homolateral upper hemithorax, likely related to rare cutaneous toxicity of the protocol (Figure 1).

Keywords: Osteochondroma; Humerus; Tumor

Figure 1: A 36 years old patient with a rare cutaneous toxicity of API protocol.